Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)

Dr. Martin Dietrich presents updated efficacy and safety data from the Phase 2 PHAROS study, evaluating encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer, showing sustained clinical activity and a consistent safety profile after extended follow-up.

Video Player is loading.
Current Time 0:00
Duration 9:50
Loaded: 0%
Stream Type LIVE
Remaining Time 9:50
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

x